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Summary. Background and Objective. Although surgery is traditionally performed for patients 
with a single brain metastasis, an increasing number of patients with multiple brain metastases may 
also be treated surgically. The objective of the study was to analyze postoperative survival results 
and the clinical factors affecting these results.
Material and Methods. The records of the patients who underwent surgical resection of 2 or 
more lesions between January 2005 and January 2010 were retrospectively reviewed. Survival was 
calculated from the date of surgery to the last follow-up evaluation or death, and different clinical 
factors were analyzed in regard to patient survival.
Results. In total, 36 patients underwent one or more craniotomies. The survival of the total group 
ranged from 16 days to 37.5 months (mean, 29 months). There were 4 deaths within 30 days. When 
divided into Radiation Therapy Oncology Group RPA classes, the survival time was 11.75, 8.58, 
and 5.31 months for classes 1, 2, and 3, respectively. Regarding an impact on the survival, a signifi-
cant association with a favorable outcome was found for the following factors: the number of brain 
metastases (2–3 vs. 4–6, P=0.046), RPA classes (1 vs. 2 or 3, P=0.0192), and extent of metastasis 
resection (all vs. partial, P=0.018).
Conclusions. Well-selected patients with multiple brain metastases appear to benefit from sur-
gery compared with historical controls of patients treated with whole-brain radiotherapy alone.
Introduction
With an increase in the early detection of prima-
ry tumors and longer survival in patients with can-
cer, the incidence of brain metastases is rising. The 
most common primary sites of brain metastases are 
lung (17%), renal cell (10.5%), and breast (5.2%) 
cancer and melanoma (8%) (1). Melanoma also has 
the highest frequency of presentation with multi-
ple metastases of all primary tumors (2). Prognosis 
for patients with brain metastases is generally poor 
(median survival, 2.3–7.1 months), and therapy is 
aimed at providing optimum quality of life while 
reducing the rates of tumor relapses (3).
For many decades, whole-brain radiotherapy 
(WBRT) has been the gold standard treatment for 
patients with cranial metastases (4). Although sur-
gery is traditionally performed for patients with a 
single brain metastasis, an increasing number of pa-
tients with multiple brain metastases are also treated 
surgically (5).
Historically, patients with multiple brain me-
tastases were considered good candidates for ag-
gressive surgical treatment because it was thought 
that they were likely to die before obtaining benefit 
(6–8). Now, with more advanced procedures (image 
guidance, intraoperative ultrasound, and functional 
neuronavigation), surgical approaches can be more 
aggressive and can provide a better outcome, such 
that multiple metastatic lesions are no longer an au-
tomatic barrier to craniotomy.
With a proper patient selection and operative and 
postoperative management, resection continues to 
play a significant and evolving role in the care of 
patients with metastatic brain tumors.
The aim of the present study was to analyze the 
clinical factors affecting postoperative survival re-
sults in patients with multiple brain metastases.
Material and Methods
The records of the patients with multiple brain 
metastases who underwent surgical resection of 2 
or more lesions in the Neurosurgery Department, 
Riga East Clinical University Hospital, between 
January 2005 and January 2010 were retrospectively 
reviewed.
Patient’s age, gender, type of primary cancer, 
Karnofsky Performance Status (KPS), time from 
the first diagnosis of cancer to the diagnosis of 
brain metastases, number of metastases at the time 
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of surgery, presence or absence of systemic diseases, 
number of craniotomies, and postoperative compli-
cations were entered into a computer database.
The patients were divided into Radiation Thera-
py Oncology Group (RTOG) recursive partitioning 
analysis (RPA) classes according to Gaspar et al. (9): 
class 1, patients under 65 years with a KPS score of 
at least 70 and who had a controlled primary disease 
and no evidence of extracranial metastases; class 3, 
patients with a KPS score of less than 70; and class 
2, all the remaining patients.
All the patients underwent surgery as an elec-
tive procedure and received antibiotic prophylaxis, 
perioperative anticonvulsants, and corticosteroids. 
The goal of all the surgical procedures was gross 
total excision. Image-guided surgical navigation 
and Cavitron ultrasonic systems were used in all the 
patients. Complications related to surgical resection 
sites were scored. The KPS score was evaluated be-
fore surgery and at hospital discharge.
The following criteria were used to define the 
cases of the patients without systemic metastases as 
having a “controlled” primary disease: patients pre-
senting with brain metastases alone when no pri-
mary site could be identified after a thorough inves-
tigation, patients presenting with synchronous brain 
metastases if the primary site was surgically resected 
or treated with radiotherapy/chemotherapy, and pa-
tients with metachronous brain metastases when no 
evidence of primary tumor recurrence was identi-
fied.
The survival was calculated from the date of 
surgery to the last follow-up evaluation or death. 
Deaths within 30 days after surgery were considered 
as perioperative mortality.
Statistical analysis was performed using the Sta-
tistical Package for the Social Sciences (SPSS) and 
MedCalcfor Windows software. Survival curves 
were estimated by the Kaplan-Meier method. A 
univariate analysis was conducted using the Mann-
Whitney U test, and a multivariate analysis was 
performed to determine which variables were sig-
nificantly associated with a difference in the survival 
under a Cox regression model.
The following factors were analyzed in regard 
to patient survival using the Mann-Whitney U test 
and Cox regression model: patient’s gender (male 
vs. female), patient’s age (≥65 vs. <65), histology 
(melanoma and breast metastases vs. all other), 
presentation (synchronous vs. metachronous), KPS 
(≥70 vs. <70), RTOG RPA class (1 vs. 2 or 3), 
number of tumors (2–3 vs. 4–6), extent of resec-
tion (resection of all lesions vs. resection of some, 
but not all lesions), and controlled primary tumor 
(yes vs. no).
Results
During the 6-year period, 36 patients diagnosed 
with multiple brain metastases underwent 1 or more 
craniotomies at our institution.
There were 18 men and 18 women with a mean 
age of 58.47 years (range, 35 to 82 years; SD, 
10.98). Fifteen patients had metastatic melanoma. 
Besides, 26 patients developed metachronous me-
tastases, whereas the others developed synchronous 
metastases (Table).
More than half of the patients (n=20) presented 
with neurological deficits, whereas other patients 
were neurologically intact preoperatively, only exe-
periencing symptoms of raised intracranial pressure 
(n=9) or seizures (n=5) or were incidentally diag-
nosed with their primary malignancy (n=2) during 
workup. Besides, 15 patients (41.66%) had a KPS 
score of at least 70.
There were 18 patients with 2 metastases, 9 
patients with 3 metastases, 6 patients with 4 me-
tastases, and 3 patients with 5 or more metastases. 
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Values are mean ± standard error. 
KPS, Karnofsky Performance Status; RPA, recursive 
partitioning analysis.
Table. Patients’ Characteristics and Survival Time 
by Different Groups
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Moreover, 20 patients had metastases located in 
the cerebral hemispheres; metastases of deep loca-
tion (referring to tumors located within the basal 
ganglia, thalamus, brainstem, corpus callosum, or 
cerebellar hemispheres) were seen in 3 patients, 
whereas 13 patients had metastases in both loca-
tions. The size of metastatic lesions ranged from 
1.2 cm to 4.6 cm.
All the lesions were removed in 15 patients; 21 
patients did not undergo resection of all known le-
sions. Furthermore, 28 patients underwent 1 cra-
niotomy, 7 patients underwent 2 craniotomies in a 
single operation, and 1 patient underwent 3 crani-
otomies in a single operation.
There were 3 postoperative complications (1 infec-
tion due to cerebrospinal fluid leak and 2 due to local 
hematomas), and 4 deaths occurred within 30 days.
The survival time ranged from 16 days to 37.5 
months (mean, 7.29 months; 95% CI, 4.60–9.98; 
SD, 7.95; SE, 1.33). When divided into RTOG RPA 
classes, the survival time was 11.75, 8.58, and 5.31 
months for classes 1, 2, and 3, respectively (Fig.). 
The use of adjuvant WBRT remains contro-
versial; therefore, only 7 patients (19.44%) with 
radiosensitive tumors (breast, lung, etc.), a stable 
systematic disease, and a good performance status 
(KPS ≥70) received WBRT (median dose, 30 Gy) 
2 weeks after surgery. Systemic chemotherapy is 
known to be largely ineffective for brain metastases 
because of the inability of most agents to penetrate 
the blood-brain barrier, and it was used only for the 
systemic disease treatment.
Because many of the patients died in other hos-
pitals or at home, it was impossible to determine 
precisely whether they died from cerebral or extrac-
erebral progression. For this reason, the cause-spe-
cific survival was not calculated.
Regarding a potential impact on the survival and 
using a univariate analysis, a statistically significant 
association with a favorable outcome was found for 
the following factors: number of brain metastases 
(2–3 vs. 4–6, P=0.046) and extent of metastasis 
resection (all vs. partial, P=0.018). A multivariate 
analysis was conducted using the same criteria, and 
a significant effect was demonstrated only for RPA 
(P=0.0192).
Discussion
Although surgery is known to play a limited role 
in patients with multiple metastases, studies have 
demonstrated its feasibility and suggest that it may 
be an effective option. This is particularly impor-
tant for patients who have multiple metastases with 
a mass effect. In a retrospective study by Bindal et 
al. (10), 56 patients with multiple brain metastases 
were surgically treated. The investigators found that 
in the cohort of the patients who had all metasta-
ses resected, the prognosis was similar to that of a 
matched cohort of the patients with a resected soli-
tary metastasis. There was no increase in morbidity. 
On the other hand, the cohort of the patients who 
did not have all the metastases surgically removed 
had a poorer prognosis. Our study showed similar 
data: significant differences in the survival were not-
ed among the patients who had all metastases re-
sected versus those who did not have all metastases 
surgically removed (10.94 months vs. 4.68 months, 
P=0.018). In other study, Wronski et al. (11) found 
no difference in the overall outcome comparing pa-
tients with a single metastasis with patients multiple 
brain metastases, all being surgically treated. How-
ever, not all studies confirm this experience (12), 
and a randomized study could help clarify this.
Patients with 4 or more brain metastases remain 
to have a particularly poor prognosis and are usually 
not treated surgically (13). Those patients with 4 
or more metastases who were surgically treated in 
our clinic also had a statistically significantly worse 
prognosis regarding the median survival compared 
with those who had 2 to 3 metastases removed 
(P=0.046).
It is important to recognize that not all patients 
will benefit from the surgical removal of brain me-
tastases, and a number of factors should be care-
fully considered when developing a treatment plan 
(5). Traditional criteria for selecting patients who 
will benefit from surgery include a good physical 
function as assessed by the KPS score, a single and 
Fig. Survival times by recursive partitioning analysis (RPA) 
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surgically accessible metastasis, and stable or absent 
extracranial metastases. The KPS ranks patients on 
their ability to carry out activities of daily life, with 
the scores of 70 or above having the best outcome 
after surgery (14). More recently, the RTOG has 
developed recursive partitioning analysis, a statisti-
cal method of classifying patients that includes the 
KPS score, patient’s age, and the status and extent 
of extracranial disease (9). Patients in RPA class 1 
status are the best candidates for craniotomy. These 
patients are characterized by the age of 65 years or 
less, the KPS score of 70 or more, the absence of 
extracranial metastases, and a good control of their 
systemic disease. RPA class 2 patients have the KPS 
score of 70 or more, but may also be aged over 65, 
and have an uncontrolled systemic disease and other 
systemic metastases. The selection of these patients 
for surgical treatment requires a careful considera-
tion of their likely duration of survival and their 
operative risks. Patients in RPA class 3 status have 
the KPS score of less than 70; these patients have 
the poorest prognosis and are usually not selected 
for surgery (15). In the current series, the median 
survival time for RPA class 1 patients with multiple 
metastases was 11.75 versus 6.21 months for patients 
in less favorable RPA classes (P=0.098). Logically, 
a more aggressive treatment should be reserved for 
patients who are functionally independent with a 
good systemic disease control. For patients in less 
favorable prognostic groups (≤RPA class 2) and with 
multiple lesions, the choice is either WBRT alone or 
a stereotactic radiosurgery (SRS) boost, according 
to clinical judgment. Moreover, adjuvant WBRT af-
ter surgery or SRS significantly reduces intracranial 
relapse and neurological death rates, but does not 
improve functional independence or overall survival 
(16).
Patients with multiple metastases often have le-
sions located too far apart to allow resection with 
a single craniotomy. Accurate localization of sub-
cortical lesions is now possible with image-guided 
stereotaxy, smaller cranial and dural openings, and 
minimal exposure of normal brain. Our data indi-
cate that multiple craniotomies are not associated 
with an increased complication rate per craniotomy 
or with higher 30-day mortality rates. However, 
patients undergoing multiple craniotomies have a 
higher cumulative probability of developing a com-
plication. In general, the need for multiple cranioto-
mies should not be a major deterrent to the decision 
to operate.
During the last 20 years, radiosurgery, in addi-
tion to surgery and WBRT, has emerged as one of 
the key options for patients with brain metastases 
because of its noninvasive nature and high lesion 
control rates (17). Since 2010, the Novalis frame-
less image-guided radiosurgery system has been ap-
plied at Riga East Clinical University Hospital. We 
have data on our initial experience in the treatment 
of patients with single or multiple brain metastases, 
and further studies are needed to match the treat-
ment results. However, surgery continues to play an 
essential role in the management of lesions that are 
complicated by a mass effect or after failure of less 
invasive treatment methods (18).
Conclusions
Well-selected patients with multiple brain metas-
tases appear to benefit from surgery compared with 
historical controls of patients treated with whole-
brain radiotherapy alone. Further prospective series 
are needed to optimize and individualize the care of 
patients with multiple brain metastases.
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